These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 18723432)

  • 1. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
    Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
    PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Vernon AA; Peloquin CA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1457-62. PubMed ID: 16141439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Zhang M; Rosenthal IM; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2009 Dec; 180(11):1151-7. PubMed ID: 19729664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
    Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
    Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
    Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
    Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.
    Andries K; Gevers T; Lounis N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4540-4. PubMed ID: 20713662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
    Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.
    Veziris N; Ibrahim M; Lounis N; Chauffour A; Truffot-Pernot C; Andries K; Jarlier V
    Am J Respir Crit Care Med; 2009 Jan; 179(1):75-9. PubMed ID: 18948422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.
    Vernon A; Burman W; Benator D; Khan A; Bozeman L
    Lancet; 1999 May; 353(9167):1843-7. PubMed ID: 10359410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
    Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection.
    Zhang T; Li SY; Williams KN; Andries K; Nuermberger EL
    Am J Respir Crit Care Med; 2011 Sep; 184(6):732-7. PubMed ID: 21659613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
    Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
    N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.